Empire Life Investments Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empire Life Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,080 shares of the biopharmaceutical company’s stock after selling 705 shares during the period. Empire Life Investments Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,906,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,510,000. Klingenstein Fields & Co. LP grew its stake in shares of Regeneron Pharmaceuticals by 1,083.7% during the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock valued at $4,848,000 after buying an additional 6,231 shares during the period. Banque Pictet & Cie SA purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $4,496,000. V Square Quantitative Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 11.9% during the 4th quarter. V Square Quantitative Management LLC now owns 1,489 shares of the biopharmaceutical company’s stock valued at $1,061,000 after buying an additional 158 shares during the period. Finally, Vontobel Holding Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 56.1% during the 4th quarter. Vontobel Holding Ltd. now owns 6,458 shares of the biopharmaceutical company’s stock valued at $4,600,000 after buying an additional 2,322 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $673.60 on Friday. The firm has a market cap of $74.02 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The firm’s 50-day simple moving average is $709.01 and its 200-day simple moving average is $900.22. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.86 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.